Cargando…
Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors
Inhibitors of the proteolytic activity of the 20S proteasome have transformed the treatment of multiple B-cell malignancies. These agents have also been employed with success in the treatment of patients with autoimmune diseases and immune-mediated disorders. However, new agents are needed to fully...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750005/ https://www.ncbi.nlm.nih.gov/pubmed/35011570 http://dx.doi.org/10.3390/cells11010009 |